XomaXOMA
Market Cap: $349M
About: XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Employees: 13
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
5% more funds holding
Funds holding: 57 [Q1] → 60 (+3) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
0.88% less ownership
Funds ownership: 66.82% [Q1] → 65.94% (-0.88%) [Q2]
3% less capital invested
Capital invested by funds: $187M [Q1] → $181M (-$5.56M) [Q2]
73% less call options, than puts
Call options by funds: $24K | Put options by funds: $90K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 102 / 272 met price target | 292%upside $117 | Buy Maintained | 15 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 38% 1-year accuracy 102 / 272 met price target | 148%upside $74 | Buy Reiterated | 9 Jul 2024 |